A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors - Wikidata - thesis-toulmin - TriplyDB

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

http://www.wikidata.org/entity/Q34483473

about

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages Tryptophan Catabolism in Chronic Viral Infections: Handling Uninvited Guests Targeting immune checkpoints in malignant glioma The Kynurenine Pathway Is a Double-Edged Sword in Immune-Privileged Sites and in Cancer: Implications for Immunotherapy Immune checkpoint blockade: a common denominator approach to cancer therapy Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells 1-Methyl-D-tryptophan potentiates TGF-β-induced epithelial-mesenchymal transition in T24 human bladder cancer cells.Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context Breast cancer and immunology: biomarker and therapeutic developments.Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.Breast Cancer Immunotherapy: Facts and Hopes.Binding properties of different categories of IDO1 inhibitors: a microscale thermophoresis study.The Janus-faced nature of IDO1 in infectious diseases: challenges and therapeutic opportunities.Immunotherapy for breast cancer: past, present, and future.Major developments in the design of inhibitors along the kynurenine pathway.Emerging Opportunities and Challenges in Cancer Immunotherapy.Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets.Modulation of cancer-specific immune responses by amino acid degrading enzymes.Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity.Dysfunctional T cell metabolism in the tumor microenvironment.Heme-containing enzymes and inhibitors for tryptophan metabolism.Docking Studies and Molecular Dynamic Simulations Reveal Different Features of IDO1 Structure.Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.Small molecule drugs with immunomodulatory effects in cancer.Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression.Discovery of IDO1 Inhibitors: From Bench to Bedside.IDO1 in cancer: a Gemini of immune checkpoints.Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer.Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression.Harnessing the immune system in the battle against breast cancer.Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.Targeting Leukemia Stem Cells in the Bone Marrow Niche.

P2860

Q26769884-3B39F426-1E2A-40FD-8BEE-1D844D096605 Q26778793-2C0696E0-197B-49F2-9282-14099D4F1D00 Q26783748-9C809B3B-C8EE-4FBB-81F5-B601B49D25B3 Q26797214-90B03490-704B-4161-916F-4A17BA4D1201 Q28072012-F65E19B7-EA43-43F2-A76B-EC487EE78459 Q28073631-AE1BA445-6AFF-42CC-B9BF-489E9151F28A Q28083981-761DBF96-B393-473A-A17F-3A97505CDC63 Q33576170-62C37864-703F-4AFF-85CB-9057B44994F2 Q33702231-4FE4B800-77C8-4115-A0B3-E8361F56F8AF Q35744133-98DB52EC-6A20-4471-83F2-7C440CED60D4 Q35757397-DF845D5E-C965-4E9B-AA3B-845869B8E924 Q36854062-CE313707-1B7E-4E97-8DAF-FF6A55EC3A98 Q37079141-F045C4A4-9FF8-4D74-85E4-ED5495EEF70D Q37669352-58D5AD51-F2B2-42B9-A3C2-F4BBBAE42122 Q38584383-928D4950-18C5-4477-BF01-89F4CD4E1269 Q38620878-FA0629A4-6F31-4C9F-8FB3-85EB083FBA0C Q38628198-0FB3C3E2-EEC8-4805-A37D-916BFD549282 Q38647699-5B6FA9AF-96ED-424C-A0F1-5AB41B8C1A85 Q38675915-D5149E35-E6C3-41C7-943D-DD71398773EB Q38787696-95B275C4-967E-487A-B45E-2A4C470BBCE9 Q38808400-CBADBBE4-B65D-4175-910E-F36B63CD4588 Q38809772-DBF6E239-F37E-4BF6-8DB7-24942DA61DDD Q38998166-8B38DA34-A4A5-4CBF-94C6-F2361D8FABA2 Q39045520-605C5864-9B4E-4BA7-A9CD-35BA4EACF1A2 Q39144794-ABB4A0B9-6882-409B-83B2-A42DC7D076EA Q39272251-9450FBCB-271D-49C6-951A-229D2D3E528D Q39398164-EB2B6844-2151-46E8-8D64-49697BD738C7 Q40816321-5B031CB5-1FAA-4ADA-B31C-B91E2478F008 Q42690881-0D2593EA-F53C-48D1-AA18-23DFF0700E4C Q45814047-727E859D-E7B8-4C35-92D7-18CA73E7596C Q46014755-A068E0C2-98C7-48C7-8298-246FE6E89F5B Q47547812-32600817-ACB7-456E-9075-865CCE2EBAAD Q47836812-EC30ABFB-FB13-4989-B3C2-76B83F854DEA Q48306002-6C28937C-FB89-4AE8-B965-4568A597C071 Q48825054-2F2C0B59-4308-4E50-899D-A835EF0CDBFD Q49544289-CCC6189C-C765-4A4F-8066-BE2AA2C4C944 Q49592866-9B36EDF5-1A4E-4B93-841F-E6AB12ADEA4C Q49884762-F3853D0D-E5BD-41B6-8080-64D7472A2D45 Q50136955-B97862AD-450E-43F2-B731-796796FA3E84 Q52375473-FACCA061-D093-4976-AF7C-F9903F02C3FA

P2860

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

http://www.wikidata.org/entity/Q34483473

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A first in man phase I trial o ...... s with metastatic solid tumors

@ast

A first in man phase I trial o ...... s with metastatic solid tumors

@en

A first in man phase I trial o ...... s with metastatic solid tumors

@nl

type

label

A first in man phase I trial o ...... s with metastatic solid tumors

@ast

A first in man phase I trial o ...... s with metastatic solid tumors

@en

A first in man phase I trial o ...... s with metastatic solid tumors

@nl

prefLabel

A first in man phase I trial o ...... s with metastatic solid tumors

@ast

A first in man phase I trial o ...... s with metastatic solid tumors

@en

A first in man phase I trial o ...... s with metastatic solid tumors

@nl

P1433

Q34483473-6BC44CB9-8574-447D-9628-57A6DFB88B95

P1476

Q34483473-4485B2C1-1DE0-4971-A865-9573A6654C6A

P2093

Q34483473-08B51FDF-57BE-481E-B938-4227F4CF867C

Q34483473-0ED0D665-1443-418E-A954-313BD82B5BB5

Q34483473-5D47D06F-B823-4595-AAA0-C21A3FD0DF99

Q34483473-6A2686B7-E3ED-4D65-A6CF-D40F51A58161

Q34483473-82F603AC-3BDD-4D54-8574-0B78FF945A89

Q34483473-96D28E67-E5EB-4C8A-B5A8-F5B4D99124DC

Q34483473-9BB3C3A3-75FC-4CA0-BCA6-8A5D275D952B

Q34483473-C89E0E49-D977-4F33-B44B-B51996745C7A

Q34483473-E6119D16-04FB-4A9D-83CE-2900FF8766CD

Q34483473-EF97651F-47D3-43AC-AB6D-EFCA0E066208

P2860

Q34483473-002E6293-2467-423B-BBBE-D673FC5A8CDE

Q34483473-11A15F07-728A-4C07-ABD0-3F3BE48CC361

Q34483473-1DA31603-D607-4994-8063-1C3833105A2A

Q34483473-35AB2173-FB57-4320-8AD2-9F4D8A9B01F3

Q34483473-42DF6D0E-B353-4B0C-93F1-729E5AA807BA

Q34483473-4A3A5231-F192-430F-9E78-56FA8549A042

Q34483473-52F42865-7FB6-4C75-8721-70FB8B4D6E48

Q34483473-57E86CF3-6A53-41B6-8101-836202B4D048

Q34483473-65CE339B-DAC4-4A0A-BC1D-A537325E0DED

Q34483473-7B425734-3946-4129-8DA1-B089F8FFCA74

P304

Q34483473-9ABA5440-4B0F-49AE-85B5-D3ABCE47284D

P31

Q34483473-B5D37ED7-3868-4D47-9A8B-1585B444F948

P356

Q34483473-91A536D3-CE24-44BA-BA76-4FFB3D8FA78D

P407

Q34483473-A6D52B7C-9815-44B3-A82A-36D489251622

P433

Q34483473-15C65011-B6F3-4C20-A473-FE26C08D92BB

P478

Q34483473-C7933777-D894-4A87-9FE1-6B8C75CD1973

P577

Q34483473-C3674B3A-898E-4819-887B-B8BB562720B5

P5875

Q34483473-C9535A48-DFF3-4B98-8A1B-80C8F93AB143

P698

Q34483473-6F14A6D7-CD4D-4CF9-B8A1-2B1B876FFA40

P921

Q34483473-43F668AA-61F0-4900-BFD0-D8C84781C480

Q34483473-DD9F70E4-C049-4D6F-9F92-6C38B26278CE

P932

Q34483473-3F1F3923-91B8-4AA4-99CA-63B19A68BA72

P356

ONCOTARGET.2357

P1433

P1476

A first in man phase I trial o ...... s with metastatic solid tumors

@en

P2093

Charles Link

http://www.w3.org/2001/XMLSchema#string

Daniel M Sullivan

http://www.w3.org/2001/XMLSchema#string

E Claire Dees

http://www.w3.org/2001/XMLSchema#string

Erica Jackson

http://www.w3.org/2001/XMLSchema#string

Hatem H Soliman

http://www.w3.org/2001/XMLSchema#string

Hyo Han

http://www.w3.org/2001/XMLSchema#string

Nicholas N Vahanian

http://www.w3.org/2001/XMLSchema#string

R Donald Harvey

http://www.w3.org/2001/XMLSchema#string

Roohi Ismail-Khan

http://www.w3.org/2001/XMLSchema#string

Scott Antonia

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Prevention of allogeneic fetal rejection by tryptophan catabolism

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Inhibition of T cell proliferation by macrophage tryptophan catabolism

Tolerance, DCs and tryptophan: much ado about IDO

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Enhancement of tumor radioresponse by docetaxel: Involvement of immune system.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

P304

8136-8146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2357

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267101778

http://www.w3.org/2001/XMLSchema#string

P698

25327557

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4226672

http://www.w3.org/2001/XMLSchema#string